Effect of Medroxyprogesterone on Duration of Non-invasive Mechanical Ventilation Among Patients With COPD

Effect of Medroxyprogestrone vs Placebo on Duration of Non-invasive Mechanical Ventilation Among Patients With Chronic Obstructive Pulmonary Disease: A double-blind controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190810044500N21

Enrollment

Registered

2022-02-01

Start date

2022-02-20

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Medroxyprogesterone 5 mg tablets (manufactured by Iran Hormone Pharmaceutical Company). Patients with COPD who admit to Rahnemoun Hospital will be randomized to the

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: pH between 7.25 and 7.35 PCO2 greater than 50 mm Hg GSC greater than 8 Lack of severe drowsiness

Exclusion criteria

Exclusion criteria: Conscious consent by the patient or the patient's companion Cystic Fibrosis or Bronchiectasis History of allergy to medroxyprogesterone Severe heart failure Severe liver failure Severe renal failure Using NIV at home Requires CPAP usage Requires endotracheal intubation and initiation of invasive ventilation

Design outcomes

Primary

Measure	Time frame
Successful winning. Timepoint: during hospitalization. Method of measurement: Separation from NIV.;Duration of use of NIV. Timepoint: at discharge time. Method of measurement: Duration of use of NIV based on day.	—

Secondary

Measure	Time frame
Duration of weaning. Timepoint: From the process of separation from the device to the patient's spontaneous breathing. Method of measurement: Counting the number of days.;Sofa score. Timepoint: Before intervention and one day, three days, seven days after, and patient discharging day. Method of measurement: Scoring based on pulmonary, coagulation, hepatic, cardiovascular, central nervous system and renal status.;Duration of hospitalization. Timepoint: at discharge time. Method of measurement: based on days.;ICU admission requirement. Timepoint: at discharge time. Method of measurement: yes/no.;ABG parameters (Na Hco3, O2Sat, PCO2, PH). Timepoint: Before intervention and one day, three days, seven days after, and patient discharging day. Method of measurement: Arterial blood samples (ABG) is taken from the patient.	—

Measure

Time frame

Duration of weaning. Timepoint: From the process of separation from the device to the patient's spontaneous breathing. Method of measurement: Counting the number of days.;Sofa score. Timepoint: Before intervention and one day, three days, seven days after, and patient discharging day. Method of measurement: Scoring based on pulmonary, coagulation, hepatic, cardiovascular, central nervous system and renal status.;Duration of hospitalization. Timepoint: at discharge time. Method of measurement: based on days.;ICU admission requirement. Timepoint: at discharge time. Method of measurement: yes/no.;ABG parameters (Na Hco3, O2Sat, PCO2, PH). Timepoint: Before intervention and one day, three days, seven days after, and patient discharging day. Method of measurement: Arterial blood samples (ABG) is taken from the patient.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Saghafi

Yazd University of Medical Sciences

F.saghafi@ssu.ac.ir+98 35 3820 3419

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 5, 2026